Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination antiretroviral therapy regimen used for the treatment of HIV-1 infection. It combines four medications: atazanavir (a protease inhibitor), ritonavir (a pharmacokinetic enhancer/booster), and the nucleoside/nucleotide reverse transcriptase inhibitors tenofovir disoproxil fumarate and emtricitabine. Atazanavir is boosted with low-dose ritonavir to optimize its pharmacokinetic parameters and efficacy. This combination has shown potent antiviral activity with once-daily dosing, making it suitable for initial HIV treatment or as part of a treatment regimen for HIV-infected individuals.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on atazanavir + ritonavir + tenofovir disoproxil fumarate + emtricitabine.